Ozempic and Vision Loss: Medication Management for PI Litigation

James Wong — Founder & CEO, LienScripts | March 4, 2026 | 7 min read

Emerging research links semaglutide (Ozempic) to non-arteritic anterior ischemic optic neuropathy (NAION) and vision loss. PI attorneys handling these claims should understand the medication management needs and how LienScripts pharmacy liens support treatment documentation.

Non-arteritic anterior ischemic optic neuropathy (NAION) is an eye condition causing sudden, painless vision loss that emerging research has linked to semaglutide (Ozempic, Wegovy) use. Studies published in medical journals have identified a statistically significant association between GLP-1 receptor agonist use and NAION, leading to personal injury claims by patients who experienced vision loss or impairment while taking these medications. Pharmacy lien services through LienScripts support these cases by covering the medications needed to manage vision-related complications and associated conditions during litigation.

• Research links semaglutide use to non-arteritic anterior ischemic optic neuropathy (NAION), a cause of sudden vision loss
• Plaintiffs with GLP-1-related vision loss require medications for ocular treatment, associated conditions, and supportive care
• LienScripts pharmacy liens cover all vision-loss-related medications during litigation at zero upfront cost
• Documented medication management strengthens the causation and damages narrative in vision loss claims
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages

Understanding the Ozempic-Vision Loss Connection

NAION occurs when blood flow to the optic nerve is disrupted, causing damage that results in sudden vision loss, typically in one eye. The condition is the most common cause of acute optic nerve damage in adults over 50. Research has identified that patients taking semaglutide may have an elevated risk of developing NAION compared to non-users.

The mechanism by which GLP-1 receptor agonists may trigger NAION is still being studied, but hypotheses include medication effects on blood vessel regulation, changes in blood pressure dynamics, and potential impacts on microcirculation to the optic nerve.

For personal injury attorneys, these cases present a pharmaceutical injury with specific medication management needs that extend well beyond the initial diagnosis.

According to James Wong, PharmD, founder of LienScripts, "Vision loss from Ozempic is a devastating injury that requires comprehensive pharmaceutical support. Patients need eye medications, may need medications for depression and anxiety caused by sudden vision impairment, and may need adjustments to other medications they were taking before the injury. The pharmacy lien covers all of this."

Medication Needs for Vision Loss Plaintiffs

Ocular Medications

Patients diagnosed with NAION may be prescribed:

• Corticosteroid eye drops to reduce optic nerve inflammation
• Intraocular pressure-lowering medications if secondary glaucoma develops
• Ocular vasodilators or medications aimed at improving blood flow to the optic nerve
• Protective eye drops and lubricants for ongoing eye health management

Mental Health Medications

Sudden vision loss causes significant psychological distress. Plaintiffs commonly require:

• Antidepressant medications for depression associated with vision impairment
• Anti-anxiety medications for adjustment disorder and anxiety about further vision loss
• Sleep medications for insomnia caused by psychological distress

Medication Adjustments

Patients who discontinue semaglutide after a NAION diagnosis may need medication adjustments for the conditions semaglutide was originally treating, including diabetes management medications and weight management alternatives.

Pain and Headache Management

Some NAION patients experience ocular pain and headaches that require analgesic medications, including NSAIDs and headache-specific treatments.

Pharmacy Lien Strategy for Vision Loss Cases

Comprehensive Medication Coverage

The LienScripts pharmacy lien covers all medications related to the vision loss injury and its downstream effects. This includes direct ocular treatment, mental health medications, medication adjustments, and supportive care. The comprehensive coverage ensures no treatment category is left unfunded during litigation.

Documented Treatment Timeline

The MERIT report from LienScripts documents when each medication was prescribed and dispensed relative to the NAION diagnosis. This timeline is critical for establishing that the medications were causally related to the injury and not pre-existing treatment needs.

For attorneys building medication documentation for settlement or trial, the MERIT report provides the pharmaceutical evidence layer for vision loss claims.

Long-Term Medication Documentation

NAION-related vision loss is often permanent or only partially reversible. Plaintiffs may require ongoing medications for years or indefinitely. The pharmacy lien documents the treatment trajectory from diagnosis forward, supporting future damages calculations for continued medication needs.

Building the Damages Narrative

Causation Support

The medication timeline helps establish causation by showing the temporal relationship between semaglutide use, NAION diagnosis, semaglutide discontinuation, and initiation of treatment medications. The MERIT report creates a clear pharmaceutical chronology.

Quality of Life Impact

The range of medications prescribed after vision loss, including mental health medications and sleep aids, documents the quality-of-life impact beyond the vision loss itself. Each additional medication category represents a dimension of the plaintiff's suffering that supports the damages claim.

Future Medication Needs

Attorneys should work with treating ophthalmologists and pharmacists to project future medication needs. Many NAION patients require lifelong ocular monitoring and medication, and some require ongoing mental health pharmacotherapy. These projections support future damages claims.

For additional guidance on building comprehensive medication evidence for cases, the vision loss case follows standard documentation principles with ophthalmology-specific considerations.

The Evolving Litigation

GLP-1 vision loss litigation is in its early stages, with research continuing to refine the understanding of the association between semaglutide and NAION. Attorneys entering this litigation space should establish pharmacy lien relationships through LienScripts early to ensure that clients receive medication coverage from the start and that the pharmaceutical treatment record is comprehensive from day one.